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Lipoprotein receptors of the LDLR family serve as
clearance receptors for b2GPI and as signaling
receptors for the b2GPI/antibody complexes in anti-
phospholipid syndrome. We compared four ligand-
binding LA modules from LDLR and ApoER2 for their
ability to bind domain V of b2GPI (b2GPI-DV). We
found that the LA modules capable of binding
b2GPI-DV interact with the same region on b2GPI-
DV using residues at their calcium-coordination site.
The structure of a complex between b2GPI-DV and
LA4 of LDLR, solved by molecular docking guided
by NMR-derived restraints and extensively validated,
represents the general mode of interaction between
b2GPI and lipoprotein receptors. We have shown
that b2GPI-DV cannot simultaneously bind to lipo-
protein receptors and anionic phospholipids, sug-
gesting that the association of b2GPI/anti-b2GPI
antibody complexes with anionic phospholipids will
interfere with lipoprotein receptors’ signaling in APS.INTRODUCTION
Beta2-glycoprotein I (b2GPI) is an abundant plasma protein with
an established function in the pathology of antiphospholipid
syndrome (APS). APS is an autoimmune disease characterized
by recurrent thrombosis and pregnancy complications, and
b2GPI is a major antigen for autoimmune antibodies in patients
with APS (Giannakopoulos et al., 2009; Urbanus et al., 2008a).
Precise molecular mechanisms leading to thrombotic complica-
tions in APS are not well understood and, as a consequence,
current options for treatment and prevention of thrombosis are
limited (Lim et al., 2006).
The presence of anti-b2GPI antibodies is accompanied by
cellular activation both in vitro and in vivo (Cugno et al., 2009;
Koike et al., 2007; Pierangeli et al., 2004). A number of cell-
surface molecules, including annexin A2 and Toll-like receptors
(TLR) on endothelial cells and monocytes, and ApoER2 and
GPIba on platelets, are suggested to play a role in APS (Cockrell
et al., 2008; Lutters et al., 2003; Pennings et al., 2007b; Raschi
et al., 2008; Shi et al., 2006; Sorice et al., 2007; Urbanus et al.,
2008b; Zhang and McCrae, 2005). The importance of annexin366 Structure 18, 366–376, March 10, 2010 ª2010 Elsevier Ltd All rigA2 and TLR-4 for the mediation of thrombogenic effects of
APS-related antibodies was demonstrated in vivo in a mouse
thrombosis model (Pierangeli et al., 2007; Romay-Penabad
et al., 2009). Annexin A2, which is not a transmembrane receptor,
binds b2GPI with high affinity even in the absence of antibodies
(Ma et al., 2000). Bridging of annexin A2 by either anti-annexin A2
antibodies or by b2GPI/antibody complexes induces expression
of adhesion molecules on endothelial cells (Zhang and McCrae,
2005). It was suggested that annexin A2 and TLR-4 may act in
concert on endothelial cells (Cockrell et al., 2008; Zhang and
McCrae, 2005). Onplatelets, ApoER2 andGPIbabind a recombi-
nant chimeric dimer of b2GPI that mimics the dimeric b2GPI/
antibody complex, and synergize in platelet activation (Pennings
et al., 2007b; Urbanus et al., 2008b).
ApoER2 is a member of the low-density lipoprotein receptor
(LDLR) family. Closely related members of the family, including
LDLR, VLDLR, ApoER2, LRP and megalin, are present in all 79
human tissues analyzed by gene expression array (Su et al.,
2004). These receptors not only mediate the cellular uptake of
lipids and nutrients from the circulation and function as scav-
enger receptors, but are also involved in fundamental signaling
processes (Herz et al., 2009; May et al., 2005; Stolt and Bock,
2006). Lipoprotein receptors were implicated in the clearance
of b2GPI bound to apoptotic cells, and it was demonstrated
that ApoER2 contribute to platelet activation by the b2GPI/anti-
body complexes (Maiti et al., 2008; Pennings et al., 2007a,
2007b; Urbanus et al., 2008b). Biochemical studies have shown
that all lipoprotein receptors can bind dimerized b2GPI and these
interactions are inhibited by RAP, which is a universal inhibitor of
ligand binding by lipoprotein receptors (Pennings et al., 2006).
Other lipoprotein receptors besides ApoER2 are expressed on
endothelial cells and monocytes and might contribute to the
activation of these cells by b2GPI/anti-b2GPI complexes, thus
playing a part in the pathology of APS (Korschineck et al.,
2001; May et al., 2005; Moestrup et al., 1992; Yang et al., 2009).
Lipoprotein receptors interact with their ligands by LA
modules of about 40 residues each, which are arranged in
sequence to form a ligand-binding domain (Blacklow, 2007).
The LA modules have little sequence homology, but adopt a
very similar three-dimensional structure. The structure of an LA
module is maintained by three disulfide bonds and a bound
calcium ion. Lipoprotein receptors interact with domain V of
b2GPI (b2GPI-DV) (van Lummel et al., 2005). All five domains
of b2GPI have similar fold and few interdomain contacts (Bouma
et al., 1999; Hammel et al., 2002; Schwarzenbacher et al., 1999).
Compared with the four N-terminal domains, b2GPI-DV has anhts reserved
Table 1. Stoichiometry of the B2GPI-DV/LA4 Complex Derived
from NMR Relaxation Data
NMR Sample R2/R1 tc(ns) MW (Da)
Estimated
MW (Da)
15N-LA4a 1.6 ± 0.2 2.7 ± 0.5 4,400
15N-B2GPI-DVb 3.2 ± 0.4 5.6 ± 0.5 9,500
15N-B2GPI-DV+LA4c 5.3 ± 0.7 7.9 ± 0.6 13,402 ± 1,571
15N-LA4 +B2GPI-DVd 4.9 ± 0.7 7.5 ± 0.7 12,222 ± 2,405
Composition of the NMR sample:
a 15 N-LA4 (300 mM).
b 15 N-B2GPI-DV (515 mM).
c 15 N-B2GPI-DV (306 mM) in the presence of LA4 (917 mM).
d 15 N-LA4 (275 mM) in the presence of B2GPI-DV (550 mM).
Structure
Structure of the b2GPI-DV/LA Complexextra disulfide bond, a flexible loop inserted close to the C
terminus of the domain, and an unusually high content of lysine
residues (18.1%) in its primary sequence.
In these studies, we uncovered the characteristic features of
the LA modules capable of binding b2GPI and determined the
structural details of the binding interface in the b2GPI/LA
complex by comparing different LA modules for their ability to
bind b2GPI. We used four different ligand-binding LA modules,
LA3, LA4, and LA6 from LDLR, and LA1 from ApoER2, as exam-
ples to investigate how LA modules interact with b2GPI. LDLR is
a primary internalization receptor for LDL. ApoER2, which has
high level of expression in the brain and testis, is critical both
for neuronal migration and for selenium uptake through endocy-
tosis of selenoprotein P (Masiulis et al., 2009). The first LA
module in ApoER2, ApoER2-A1, was shown to contribute the
most to the binding of dimeric b2GPI (Pennings et al., 2007a).
Both LA3 and LA4 bind RAP (Fisher et al., 2006), which also
inhibits the interaction between dimeric b2GPI and lipoprotein
receptors (Pennings et al., 2006).
Using solution nuclear magnetic resonance (NMR) spectros-
copy, we have shown that the LA modules capable of binding
b2GPI-DV interact with the same site on b2GPI-DV by residues
at their calcium-coordination region. We solved the structure of
a complex between b2GPI-DV and LA4 by molecular docking
guided by NMR-derived restraints. In the structure, extensively
validated by binding studies and site-directed mutagenesis,
the contact site for LA modules on b2GPI-DV is formed by
3 lysine residues: K308, K317, and K282. The structure of the
b2GPI-DV/LA4 complex represents how b2GPI-DV interacts
with LA modules and establishes the characteristic features
that distinguish LA modules capable of binding b2GPI. We have
shown that b2GPI-DV cannot simultaneously bind to lipoprotein
receptors and anionic phospholipids, suggesting that the associ-
ation of b2GPI/antibody complexes with anionic phospholipids
will interfere with lipoprotein receptors’ signaling in APS.
RESULTS
Stoichiometry of the b2GPI-DV/LA4 Complex
We determined the stoichiometry of binding between b2GPI-
DV and LA4 by measuring R1 and R2 relaxation rates for the
backbone amides of 15N-labeled b2GPI-DV and 15N-labeled
LA4 in isolation and in the presence of unlabeled interacting
domains at saturating concentrations. The measured relaxationStructure 18, 3rates were used to calculate an overall rotational correlation
time, tc, for the labeled molecules (Table 1). The values of tc
for LA4 and b2GPI-DV in isolation are consistent with previously
published data (Beglova et al., 2001; Hoshino et al., 2000). The
effective molecular weight of the b2GPI-DV/LA4 complex esti-
mated from the NMR relaxation measurements indicates that
the complex has 1:1 stoichiometry (Table 1).
Mapping the Binding Site for LAModules onto b2GPI-DV
To determine which residues of b2GPI-DV form the contact
site for LA modules, we monitored changes in the spectra of the
15N-labeled b2GPI-DV in the presence of different LA modules.
The residues of the flexible C-terminal loop of b2GPI-DV from
H310 to A320 are either weak or missing from the spectra and,
therefore, excluded from the analysis. Comparison of the chem-
ical shift perturbation spectra of b2GPI-DV revealed that the
same subset of residues is perturbed by LA4, LA3, and
ApoER2-A1 (Figures 1A–1E). In addition to these core residues
that likely comprise the major contact site for LA modules on
b2GPI-DV, another group of residues is perturbed by LA4 and
ApoER2-A1, suggesting that both LA4 and ApoER2-A1 form
additional contacts with b2GPI-DV that are not present in the
b2GPI-DV/LA3 complex. Finally, several additional b2GPI-DV
residues are perturbed when ApoER2-A1 is used for titration.
The perturbation of the residues I263, M271, and I301, which
form a hydrophobic cluster in b2GPI-DV, suggests that the
binding of ApoER2-A1 to b2GPI-DV affects the backbone struc-
ture of b2GPI-DV distant from the contact site. The extent of
perturbations caused by different LA modules suggests that
ApoER2-A1 binds b2GPI-DV with a higher affinity than LA4 or
LA3, and that LA3 has the weakest affinity for b2GPI-DV.
The Binding Affinities of b2GPI-DV to LA Modules
Measured by Fluorescence Polarization
Changes in the global mobility of the fluorescently labeled LA
modules upon binding to b2GPI-DV are reflected in an increase
in the measured fluorescence polarization (Figure 2). Fitting of
the binding curves resulted in the Kd values of 1.14 ± 0.06 mM
and 46 ± 7 mM for the b2GPI-DV/ApoER2-A1 and b2GPI-DV/LA4
complexes, respectively. The binding of LA3 to b2GPI-DV did
not reach saturation even when 1 mM b2GPI-DV was added to
LA3 (data not shown), suggesting that Kd for this complex is in
a high micromolar range. The increase in viscosity of the protein
solutionathighproteinconcentration,whichwould lead toanover-
estimation ofKd (Lefebvre, 1982), precluded us frommeasuringKd
of the b2GPI-DV/LA3 complex by fluorescence polarization.
Mapping the Binding Site for b2GPI-DV onto LAModules
The 15N-labeled LA modules, LA4 and ApoER2-A1, were titrated
with unlabeled b2GPI-DV to identify the residues perturbed by
complex formation (Figures 3A–3E). The relatively small changes
in the chemical shifts of the backbone amides of the LA modules
in the presence of b2GPI-DV suggest that these modules bind
b2GPI-DV predominantly by the side chains. For both LA
modules, the majority of perturbed residues are either directly
involved in coordination of the calcium ion or are adjacent to
the calcium-binding residues, suggesting that the contact site
for b2GPI-DV on the LA modules overlaps with the calcium-
binding site. Two residues from the hydrophobic core of the66–376, March 10, 2010 ª2010 Elsevier Ltd All rights reserved 367
Figure 1. Interaction of b2GPI-DV with LA
Modules
(A–C) Superposition of 15N-HSQC spectra of
184 mM b2GPI-DV in isolation (black) and in the
presence of 400 mM LA4 (A), LA3 (B), and
ApoER2-A1 (C). Perturbed residues of b2GPI-DV
are labeled.
(D and E) Perturbed residues of b2GPI-DVmapped
onto the structure (D) and the primary sequence of
b2GPI-DV (E). Residues of b2GPI-DV that are per-
turbed when b2GPI-DV is titrated with LA3, LA4,
and ApoER2-A1 (red); with LA4 and ApoER2-A1
(orange); with ApoER2-A1 (purple). Residues that
are missing from the 15N-HSQC spectra of
b2GPI-DV are colored gray. The NH groups of
tryptophan side chains are marked 3W on (E).
Structure
Structure of the b2GPI-DV/LA ComplexLA4 module, F132 and I140, and the corresponding I26 of
ApoER2-A1 are also perturbed in the presence of b2GPI-DV.
Because the structure of the LA modules is dependent on the
bound calcium ion, the perturbation of the residues in the hydro-
phobic core of the LAmodules supports our observation that the
binding interface for b2GPI-DV on LA modules is centered at the
calcium-binding site.
Docking Model of the b2GPI-DV/LA4 Complex
Because the structures of LA4 and b2GPI-DV are available in the
Protein Data Bank (PDB) database, we used these molecules for
docking. We built a docking model of the b2GPI-DV/LA4
complex using the program HADDOCK2.0 and the interaction
restraints derived from the NMR data. The clustering of the 200
refined structures resulted in only two clusters with more than
10 structures in each. The first cluster of 141 structures had an
average HADDOCK score of 97.7 ± 13.5, and the second
cluster of 26 structures had an average HADDOCK score of
70.3 ± 12.4. The best-scoring structure belongs to the most368 Structure 18, 366–376, March 10, 2010 ª2010 Elsevier Ltd All rights reservedpopulatedfirstcluster, stronglysuggesting
that it represents a correct solution. The
ensemble of the 20 best-scoring struc-
tures from the first cluster has 1.08 ± 0.47
A˚ of an overall backbone root-mean-
square deviation (rmsd) from the average
structure, indicating that the complex is
well defined (Figure 4A and Table 2). The
calculated structures have good geometry
and occupy the allowed and most favor-
able regions on the Ramachandran plot.
Structural Features
of the b2GPI-DV/LA4 Complex
The intermolecular interface in the b2GPI-
DV/LA4 complex (PDB ID 2KRI) is main-
tained by a number of hydrogen bonds
and hydrophobic contacts (Table 3). As
clearly seen from Table 3, the majority of
intermolecular contacts are created by
K308 and K317 of b2GPI-DV. These con-
tacts are further augmented by the
hydrogen bonds between K282 ofb2GPI-DV and aspartates 147 and 149 of LA4. The intermolec-
ular interface in the complex is relatively small and maintained
primarily by electrostatic interactions between positively
charged lysine residues of b2GPI-DV and negatively charged
aspartates of LA4 grouped around the bound calcium ion (Table
3 and Figures 4B and 4C). A solvent-accessible surface area of
b2GPI-DV buried in the interface of the b2GPI-DV/LA4 complex
with a minimal HADDOCK score is 455 A˚2.
Validation of the Model
Weused four different approaches to validate the dockingmodel
of the b2GPI-DV/LA4 complex. First, we mutated the critical
lysine residues of b2GPI-DV, K308, K317, and K282 to aspar-
tates and evaluated the binding of mutants to LA4 (Figures 5A
and 5B). The absence of perturbations on the 15N-HSQC spectra
of the mutants in the presence of LA4 suggests that the mutants
are incapable of binding LA4 as predicted by themodel. Second,
the b2GPI-DV/LA4 structure shows that the N148/E mutation of
LA4 may create an additional hydrogen bond with K282, leading
Figure 2. Binding of b2GPI-DV to LA Modules Determined by
Fluorescence Polarization
Atto488-labeled LA4 (triangles) and Atto488-labeled ApoER2-A1 (circles)
were titrated with unlabeled b2GPI-DV. Results are expressed as mean and
standard deviation (± SD) (n = 3).
Structure
Structure of the b2GPI-DV/LA Complexto a tighter complex. Kd of the N148/E mutant is 9.0 ± 1.6 mM
compared with 46 ± 7 mM of the b2GPI-DV/LA4 complex
(Figure 5C). Interestingly, N148 of LA4 corresponds to E34 in
the ApoER2-A1 module, which binds b2GPI-DV with 1.14 ±
0.06 mM affinity. Third, we confirmed that the lysine residues
from b2GPI-DV are critical for the interaction with the LA
modules and that the binding interface of the complex overlaps
with the calcium coordinating residues of the LA module. We
selected the sixth LA module from the LDLR. The structure of
LA6 is very similar to LA4 (Clayton et al., 2000; North and
Blacklow, 2000), but LA6 contains an arginine residue in the pre-
dicted binding interface. This arginine corresponding to W144
in the primary sequence of LA4 will interfere with the lysines
in the binding site of b2GPI-DV, precluding complex formation.
The absence of any perturbations in the spectra of 15N-LA6 in
the presence of b2GPI-DV confirms that LA6 does not bind
b2GPI-DV (Figure 5D). Fourth, we monitored changes in the
intrinsic fluorescence of W316, the only tryptophan residue of
b2GPI-DV, upon complex formation. For the titration experi-
ments we used LA3, which does not have tryptophan in its
primary sequence. The fluorescence of W316 decreases gradu-
ally upon titration with LA3, confirming that W316 is close to the
binding interface in the complex (Figure 5E and Table 3). The
emission maximum of W316 is 357 nm and does not change in
the presence of LA3, suggesting that W316 remains in the polar
environment even when LA3 is bound. This observation is in
agreement with the structure of the b2GPI-DV/LA complex,
which shows that W316 is in the periphery of the binding inter-
face. Kd of the b2GPI-DV/LA3 complex roughly estimated from
the concentration of LA3 at half-maximum binding is about
75 mM, which is in accordance with our observation that LA3
interacts with b2GPI-DV with a weaker affinity than LA4.
LA Modules Inhibit Binding of b2GPI-DV to Cardiolipin
A sequence of hydrophobic residues 313–316 (Mehdi et al.,
2000) and a lysine-rich region from residue 281 to 288 (Hunt
and Krilis, 1994; Sheng et al., 1996) are both important forStructure 18, 3b2GPI-DV binding to anionic phospholipids. In the complex,
LA4 wedges between these two regions. Therefore, we evalu-
ated, if LA modules interfere with the binding of b2GPI-DV to
cardiolipin. b2GPI-DV bound to cardiolipin was detected by a
horseradish peroxidase (HRP)-conjugated antibody directed to
HA tag added at the N terminus of b2GPI-DV (HA-b2GPI-DV).
First, we compared the binding affinities for cardiolipin of a
monomeric HA-b2GPI-DV and of HA-b2GPI-DV dimerized by
anti-HA antibodies. A concentration of HA-b2GPI-DV at half-
maximum binding was 22 ± 4 nM and 1.6 ± 0.3 nM for mono-
meric HA-b2GPI-DV and for HA-b2GPI-DV preincubated with
antibodies, respectively (Figure 6A). As expected, the binding
affinity of domain V for cardiolipin is close to that of a full-length
b2GPI (Hagihara et al., 1995) and the dimerization of HA-b2GPI-
DV increased the apparent affinity of HA-b2GPI-DV for cardioli-
pin more than 10-fold (van Lummel et al., 2005). When the
total concentration of HA-b2GPI-DV is 10 mM and above, HA-
b2GPI-DV saturates all available antibodies and free HA-
b2GPI-DV competes with HA-b2GPI-DV/antibody complexes
for binding sites on cardiolipin, resulting in diminished binding
of the complexes to cardiolipin and lower measured OD
(Figure 6A).
To investigate whether LA modules interfere with the binding
of HA-b2GPI-DV to cardiolipin, we used either LA4 or a pair of
the modules, LA3-4. We have already shown above that each
of these modules, LA3 and LA4, can bind b2GPI-DV. A gradual
decrease of bound HA-b2GPI-DV indicates that both LA4 and
LA3-4 interfere with the binding of HA-b2GPI-DV to cardiolipin.
The shape of the inhibition curve strongly suggests that
LA3-4 competes with cardiolipin for the same binding site on
HA-b2GPI-DV. The concentration of LA3-4 that inhibits 50% of
binding of HA-b2GPI-DV to cardiolipin was 106 ± 9 mM (Fig-
ure 6B). The apparent Ki of LA3-4 for HA-b2GPI-DV in the pres-
ence of anti-HA antibodies was calculated using an affinity
partitioning approach to estimate amount of HA-b2GPI-DV
bound to LA3-4 (Olson et al., 1991). Assuming that the amount
of HA-b2GPI-DV bound to cardiolipin is much smaller than the
total amount of HA-b2GPI-DV, the calculated apparent Ki of
LA3-4 was 6 mM.
This experiment provides additional validation for the structure
of the b2GPI-DV/LA4 complex, confirms that LA3 and LA4 inter-
acts with the same site on b2GPI-DV, and shows that a pair of LA
modules binds b2GPI-DV dimerized by antibody significantly
stronger than a single LA module binds b2GPI-DV. It also
demonstrates that the interactions of b2GPI-DV with lipoprotein
receptors and negative phospholipids are mutually exclusive.
DISCUSSION
ApoER2, a lipoprotein receptor expressed on platelets, functions
as a signaling receptor for dimeric b2GPI (Lutters et al., 2003;
Pennings et al., 2007a, 2007b; Urbanus et al., 2008b). Besides
platelets, several members of the LDLR family are expressed
on endothelial cells and monocytes, and might contribute to
thrombosis in APS. We used solution NMR spectroscopy,
molecular docking, and binding studies to investigate and
compare the structural features of the complexes between
b2GPI-DV and the ligand-binding LA modules from lipoprotein
receptors.66–376, March 10, 2010 ª2010 Elsevier Ltd All rights reserved 369
Figure 3. Mapping the Contact Site For b2GPI-DV onto LA Modules
(A and B) Superposition of the 15N-HSQC spectra of 100 mM LA4 in isolation (black) and in the presence of 1:0.75 (green) and 1: 2 (red) molar ratio of LA4 to
b2GPI-DV (A). Superposition of the 15N-HSQC spectra of 100 mM ApoER2-A1 in isolation (black) and in the presence of 1:0.5 (green) and 1:2 (red) molar ratio
of ApoER2-A1 to b2GPI-DV (B). Residues of the LA modules that moved above average in the presence of b2GPI-DV are labeled. The NH groups of tryptophan
side chains are labeled 3Trp.
(C and D) Combined, 1H and 15N, chemical shift perturbations of LA4 (C) and ApoER2-A1 (D) in the presence of saturating amount of b2GPI-DV. Chemical shift
difference is calculated as D = sqrt(DH**2+(0.2*DN)**2). The last bars on both panels correspond to tryptophan side chains and are marked by asterisks.
(E) Chemical shift perturbations mapped onto the primary sequence of LA modules. Residues that are shifted above average are colored pink and the residues
shifted more than 1.5 standard deviations above average are colored green. The calcium coordinating residues are labeled by filled black circles and the disulfide
bonds are indicated by lines. The sequence alignment was done with ClustalW.
Structure
Structure of the b2GPI-DV/LA ComplexThe Docking Model of the b2GPI-DV/LA4 Complex
Is Supported by Independent Experimental Data
We solved the structure of the b2GPI-DV/LA complex by molec-
ular docking guided by the NMR-derived restraints. This is the
preferred approach in the case of the b2GPI-DV/LA complexes.
Our NMR titration studies have shown that the binding interface
in the complexes is relatively small and formed predominantly by
the side chains, suggesting that it might not yield enough
distance restraints for accurate structure determination by
NMR. The relatively weak affinity of b2GPI-DV for the LA
modules makes crystallization of the complex difficult. For the
modeling studies, we selected LA4 because its structure is avail-
able in the PDB database. The carbohydrate chains of b2GPI are
not expected to interfere with the b2GPI-DV/LA complex and,
therefore, are not taken into account for the modeling. b2GPI370 Structure 18, 366–376, March 10, 2010 ª2010 Elsevier Ltd All righas four N-linked glycosylation sites at the residues N143,
N164, and N174 in domain III and N234 in domain IV. All four
glycosylation sites are far from the binding interface for LA
modules.
The structure of the complex is consistent with independent
experimental observations. First, we confirmed the structure
by site-directed mutagenesis. Based on the structure of the
b2GPI-DV/LA4 complex we selected two types of mutations.
One type of mutations disrupts the complex formation and the
other creates additional hydrogen bonds improving the binding
affinity of the complex. Mutation of the critical lysine residues
of b2GPI-DV, K308, K317, and K282, to aspartates completely
abolished the binding of LA4 to the b2GPI-DV mutant. The
N148/E mutation of LA4 resulted in a tighter complex with Kd
9.0 ± 1.6 mM compared with 46 ± 7 mM of LA4. Second, thehts reserved
Figure 4. Structure of the b2GPI-DV/LA4 Complex
(A) Superposition of 20 best structures. The polypeptide chains of b2GPI-DV and LA4 are green and blue, respectively, and the calcium ions bound to LA4 are gray
spheres.
(B) Stereoview of the overall structure of the b2GPI-DV/LA4 complex. b2GPI-DV (brown) and LA4 (green) are illustrated as ribbons. The transparent molecular
surface of b2GPI-DV is colored light brown. The calcium ion bound by LA4 is shown as a gray sphere.
(C) Interface between b2GPI-DV and LA4. The backbone traces of b2GPI-DV (brown) and LA4 (green) are shown as ribbons and the calcium ion is a gray sphere.
The interacting side chains are rendered as sticks and labeled.
Structure
Structure of the b2GPI-DV/LA Complexstructure of the b2GPI-DV/LA4 complex is consistent with previ-
ously published data for the W316/Ser mutant of b2GPI
(Pennings et al., 2006; van Lummel et al., 2005). The mutation
had no effect on the binding of dimeric b2GPI to immobilized
soluble ApoER2, VLDLR, LRP, and megalin and to ApoER2 ex-
pressed on the platelet surface. In the b2GPI-DV/LA4 structure,
this mutation does not create clashes between b2GPI-DV and
LA4 and, therefore, does not disrupt the complex. Third, the
b2GPI-DV/LA4 complex built by two different computational
docking approaches HADDOCK and PIPER (Beglov et al.,
2009) converged into nearly identical structures with a backbone
rmsd of only 0.5 A˚.
Structure of the b2GPI-DV/LA4 Complex Represents
the General Mode of Interaction between b2GPI
and Lipoprotein Receptors
Our results show that not all LAmodules can bind b2GPI-DV, and
that those LA modules capable of binding b2GPI-DV will interact
with it in the same fashion as observed in the structure of the
b2GPI-DV/LA4 complex.
We have demonstrated by solution NMR spectroscopy that
LA3, LA4, and ApoER2-A1 bind to the same site on b2GPI-DV,Structure 18, 3and that the binding site for b2GPI-DV on these LA modules is
centered on the residues involved in coordination of the calcium
ion. The dissociation constants measured here for different LA
modules are in the range from 1 mM (for ApoER2-A1) to more
than 100 mM (for LA3). The difference in the binding affinity is
due to the auxiliary contacts that augment the interactions of
the residues at the core of the binding interface. These auxiliary
contacts depend on the primary sequence of the LA modules.
When we mutated N148 of LA4 to glutamate to resemble E34
at the corresponding position in ApoER2-A1, which binds
b2GPI-DV with 1 mM affinity, we improved Kd of LA4 by a factor
of five. The changes in the intrinsic fluorescence of W316 of
b2GPI-DV upon titration with LA3 confirmed that W316 is close
to the binding interface and remains solvent exposed in the
b2GPI-DV/LA3 complex, similarly to what is observed in the
b2GPI-DV/LA4 complex.
LA modules capable of binding b2GPI could be distinguished
based on the primary sequence in the vicinity of the calcium-
coordinating residues of the LA modules. Specifically, the side
chains of amino acids at the position in the primary sequence
equivalent to D147, D149, and D151 of LA4, the immediate
neighbors of these residues as well as the residues equivalent66–376, March 10, 2010 ª2010 Elsevier Ltd All rights reserved 371
Table 2. Structural Statistics for the Twenty Best-ScoringB2GPI-
DV/LA4 Structures
B2GPI-DV/LA4
Complex
Backbone rmsd (A˚) with respect to average structure
All atoms 1.08 ± 0.47
Atoms in the interface 1.04 ± 0.47
Atoms in the interface of B2GPI-DV 0.84 ± 0.28
Atoms in the interface of LA4 1.49 ± 0.49
CNS intermolecular energies after water
refinement (kcal/mol)
Evdw 6 ± 6
Eelec 599 ± 31
Buried surface area (A˚2) 887 ± 66
Rmsd from idealized covalent geometry
Bonds (A˚) 0.00362 ± 0.00008
Angles (deg) 0.56 ± 0.02
Impropers (deg) 0.50 ± 0.02
Ramachandran analysis of the average structure
Residues in the favored region (%) 84.5
Residues in additionally allowed region (%) 15.5
Table 3. Statistics of the Intermolecular Contacts Calculated for
the Ensemble of the Twenty Best-Scoring Structures
Donor Acceptor
Hydrogen
Bonds S-Sa S-Bb
Nonbonded
Contacts
Lys282 (B2GPI-DV) Asp147 (LA4) 11 11
Asp149 (LA4) 13
Lys308 (B2GPI-DV) Asp147 (LA4) 20
Asp149 (LA4) 17
Asp151 (LA4) 19
Lys317 (B2GPI-DV) Asp149 (LA4) 16
Pro150 (LA4 20
Asp151 (LA4 19
Lys284 (B2GPI-DV) Asp147 (LA4) 15
Lys305 (B2GPI-DV Leu143 (LA4) 13
Lys308 (B2GPI-DV) Trp144 (LA4) 20
Trp316 (B2GPI-DV) Pro150 (LA4) 15
Lys317 (B2GPI-DV) Asp149 (LA4) 17
Intermolecular contacts are reported only if present in at least 10 out of 20
structures.
a Side chain/side-chain contacts.
b Side chain/backbone contacts.
Structure
Structure of the b2GPI-DV/LA Complexto L143 and W144 should not interfere with lysine side chains of
b2GPI-DV. Based on the outlined criteria, each lipoprotein
receptor contains several LA modules that can bind b2GPI.
LDLRhas the least numberof LAmodules (LA3,LA4, andpossibly
LA5) available for interactionwithb2GPI,whichmight explainwhy
LDLR has the weakest binding affinity for the b2GPI/antibody
complexes in binding studies (Pennings et al., 2006).
The spatial orientation of the side chains in the contact inter-
face of the b2GPI-DV/LA4 complex strongly resembles that
observed in the crystal structure of the RAP/LA3-4 complex
(Fisher et al., 2006). The arrangement of aspartates from LA4
around K308 from b2GPI-DV is very similar to that around
K256 of RAP. As in the RAP/LA3-4 structure, two other lysines
of b2GPI, K282 and K317, in the vicinity of K308 additionally
stabilize the b2GPI-DV/LA4 complex. Our data strongly suggest
that the general mode of recognition of basic ligands by the LA
modules is directly applicable to the complexes between
b2GPI and lipoprotein receptors.
Effect of Avidity in Interaction between b2GPI
and LA Modules
We have shown that a single LA module binds b2GPI-DV with
only micromolar affinity. Compared with a single LA module, a
pair of modules connected by a flexible linker was able to
efficiently bind HA-tagged b2GPI-DV dimerized by anti-HA
antibodies and inhibit its attachment to cardiolipin. Although
LA3 binds b2GPI-DV with low affinity (Kd > 100 mM), its presence
in the LA3-4 pair significantly improved the binding of the LA
module-pair to dimerized b2GPI-DV. Typically, lipoprotein
receptors use several LA modules connected by flexible linkers
to bind diverse ligands which, in turn, have binding sites for
several LA modules, suggesting that a single module would be
insufficient to confer high-affinity binding (Andersen et al.,
2003; Fisher et al., 2004). The modular organization of the372 Structure 18, 366–376, March 10, 2010 ª2010 Elsevier Ltd All rigligand-binding domains of lipoprotein receptors, in combination
with the flexibility of the linkers connecting individual LAmodules,
is tailored to accommodate ligands that contain multiple binding
sites. The correlation between the presence of anti-b2GPI anti-
bodies and the development of APS might underscore the role
of lipoprotein receptors in the pathology of APS. b2GPI/antibody
complex engages two LA modules, significantly stabilizing the
b2GPI/anti-b2GPI/receptor complex on the cellular surface. In
neurons, clustering of ApoER2 and VLDLR by Reelin starts the
intracellular signaling (Strasser et al., 2004). It is possible that
the dimerization of lipoprotein receptors by b2GPI/antibody
complexes also contributes to the pathology of APS.
The Binding of b2GPI to Lipoprotein Receptors
versus Anionic Phospholipids
The structure of the b2GPI-DV/LA complex and the observation
that the LA modules inhibit binding of b2GPI-DV to cardiolipin
indicate that b2GPI cannot simultaneously interact by its domain
V with lipoprotein receptors and anionic phospholipids. When
bound to b2GPI-DV, LA modules prevent two phospholipid-
binding regions on b2GPI (residues 282–287 and 313–316)
from simultaneously reaching the cellular membrane. On the
other hand, when b2GPI is bound to the cellular surface, the
binding site for LA modules is not accessible even though LA
does not bind residues that interact with phospholipids. We per-
formed cardiolipin binding and inhibition studies at low ionic
strength to match the buffer used for NMR titration studies and
to minimize the amount of proteins used in the experiment. We
do not expect that the presence of sodium ions at physiological
concentration alters the structure of the b2GPI-DV/LA complex.
The LA module inserted between the two phospholipid-binding
regions of b2GPI-DV in the complex will still interfere with the
binding of b2GPI to anionic phospholipids, although the binding
of b2GPI-DV to both LA and phospholipids will be attenuated by
the increased ionic strength.hts reserved
Figure 5. Validation of the b2GPI-DV/LA4 Structure
(A and B) Site-directed mutagenesis in combination with NMR studies. 15N-HSQC spectrum of 200 mM b2GPI-DV K282,308/D mutant (black) is overlaid with the
spectrum of 190 mM b2GPI-DV K282,308/D in the presence of 400 mM LA4 (red) (A). 15N-HSQC spectrum of 275 mM b2GPI-DV K282,308,317/D mutant (black) is
overlaid with the spectrum of 200 mM b2GPI-DV K282,308,317/D in the presence of 445 mM LA4 (red) (B).
(C) Site-directed mutagenesis in combination with fluorescence polarization measurements. Fluorescence polarization of Atto488-labeled LA4 (triangles) and
Atto488-labeled LA4 Asn148/Glu mutant (circles) titrated with b2GPI-DV. Results are expressed as mean ± SD (n = 3).
(D) Superposition of the 15N-HSQC spectra of 200 mM 15N-LA6 in isolation (black) and in the presence of 200 mM b2GPI-DV (red). The side chains are shown by
horizontal lines.
(E) Superposition of the fluorescence emission spectra of 100 mM b2GPI-DV. For each spectrum, the corresponding amount of LA3 is indicated. Fluorescence
maximum recorded at 357 nm is expressed as mean ± SD (n = 3) and is labeled by a black circle with an error bar.
Structure
Structure of the b2GPI-DV/LA ComplexNormally, anionic phospholipids are present on the inner
leaflet of the cellular membrane and become exposed on acti-
vated or apoptotic cells (Zwaal and Schroit, 1997). The content
of phosphatidylserine on the outer membrane of nonactivated
cells is about 7% (Murphy et al., 1992). The measured binding
affinity of b2GPI for phospholipid membrane composed of
10%/90% PS/PC in the presence of 120 mM NaCl and 3 mM
CaCl2 was 14 mM for monomeric b2GPI and 0.4 mM for b2GPI/
antibody complexes (Willems et al., 1996). The increase of phos-
phatidylserine to 20% resulted in amuch better binding of b2GPIStructure 18, 3to phospholipids. The measured affinity of b2GPI/antibody
complexes improved to 75 nM and 5 nM in the presence and
absence of calcium ions (Willems et al., 1996). Similarly, the
measured Kd of the dimeric b2GPI for 20%/80% PS/PC in the
absence of calcium was 18 nM (van Lummel et al., 2005).
Because lipoprotein receptors bind dimeric b2GPI with a low
nanomolar affinity (Pennings et al., 2006), the interactions of
b2GPI/antibody complexes with lipoprotein receptors will not
be efficient on activated cells exposing high levels of phosphati-
dylserine.66–376, March 10, 2010 ª2010 Elsevier Ltd All rights reserved 373
Figure 6. Binding of b2GPI-DV to Car-
diolipin
(A) Binding of HA-b2GPI-DV (inverted black trian-
gles) and HA-b2GPI-DV preincubated with anti-
HA antibody (black circles) to cardiolipin. Results
are expressed as mean ± SD (n = 3).
(B) Inhibition of binding of HA-b2GPI-DV to cardio-
lipin. Monomeric HA-b2GPI-DV was incubated
with increasing amounts of LA4 (inverted black
triangles); HA-b2GPI-DV was first preincubated
with anti-HA antibodies and then incubated
with increasing amounts of the LA3-4 module-
pair (black circles). Results are expressed as
mean ± SD (n = 3).
Structure
Structure of the b2GPI-DV/LA ComplexOn platelets, the signaling by dimeric b2GPI involves two
receptors, ApoER2 and GPIba (Urbanus et al., 2008b). Both
receptors act independently and neither receptor alone is suffi-
cient to support platelet adhesion to fibronectin. The dimeric
W316/Ser mutant of b2GPI that cannot bind to anionic phospho-
lipids does not support platelet adhesion either (Lutters et al.,
2003; van Lummel et al., 2005). Because the W316/Ser mutant
binds ApoER2 similarly to wild-type b2GPI (van Lummel et al.,
2005), it is likely that the mutation perturbs the binding of
b2GPI to GPIba. Because the binding site for GPIba on b2GPI
is in domain V (Pennings et al., 2007b), it is conceivable that
the W316/Ser mutation interferes with the binding of dimeric
b2GPI to GPIba, abolishing platelet activation.
Current knowledge indicates that APS-related antibodies only
predispose to thrombosis. Despite the presence of persistent
antibodies, APS patients do not continuously suffer from throm-
bosis, which is often triggered by infection or trauma (Sherer
et al., 2007; Shoenfeld et al., 2008; Urbanus et al., 2008a). In
in vivo experiments, thrombosis must be provoked by infection
or vessel injury (Fischetti et al., 2005; Jankowski et al., 2003;
Pierangeli et al., 1996). Adhesive surfaces are required for
detectable platelet activation by dimeric b2GPI in vitro (Lutters
et al., 2003; Urbanus et al., 2008b; van Lummel et al., 2005).
Lipoprotein receptors are constitutively expressed in different
combinations on cellular membranes of endothelial cells, mono-
cytes, and platelets. Acting in parallel with other receptors,
b2GPI/antibody complexes bound to lipoprotein receptorsmight
continuously sensitize cells, making them vulnerable to other
prothrombotic factors. On endothelial cells annexin A2 provides
high-affinity binding sites for b2GPI/antibody complexes (Ma
et al., 2000; Zhang and McCrae, 2005). The binding site for an-
nexin A2 on b2GPI and whether lipoprotein receptors act along-
side with annexin A2 on stimulation of endothelial cells are not
yet known.
The role of lipoprotein receptors expressed on endothelial cells
and monocytes in the pathology of APS and the signaling path-
ways initiated by lipoprotein receptors in response to b2GPI/anti-
body complexes are not well understood. Our structural and
binding studies might be helpful in further research addressing
the contribution of lipoprotein receptors to the pathology of APS.
EXPERIMENTAL PROCEDURES
Proteins
The fragments of the human LDLR (residues 86–122 [LA3], 126–165 [LA4], and
212–251 [LA6]) and mouse ApoER2 (ApoER2-A1 residues 12–47) were ex-374 Structure 18, 366–376, March 10, 2010 ª2010 Elsevier Ltd All rigpressed in E. coli and purified from inclusion bodies as previously described
(North and Blacklow, 2000). b2GPI-DV (residues 244–326) was subcloned
into a pET15b vector (Novagen). The encoded protein has an N-terminal histi-
dine tag followed by the sequence recognized by the tobacco etch virus (TEV)
protease so that the His tag can be removed. b2GPI-DV expressed in E. coli
was recovered from inclusion bodies, cleaved with TEV, and refolded under
conditions permitting disulfide exchange before final purification by reverse-
phase high-performance liquid chromatography (HPLC) on a C18 column.
NMR Spectroscopy
For NMR spectroscopy, the labeled protein domains were produced in M9
minimal media supplemented either with 13C6-D-glucose and/or
15N ammo-
nium chloride. All NMR experiments were conducted on a Varian Inova
500MHz spectrometer equipped with four RF channels and a triple-resonance
probe with pulsed-field gradients. Spectra were acquired at 298 K using
BioPack (Varian Inc.) pulse sequences and processed with GIFA v4.3 software
(Pons et al., 1996). Chemical shifts were referenced to 2,2-dimethyl-2-silapen-
tane-5-sulfonate sodium salt (DSS) used as an internal reference. The buffer
used for the NMR experiments contained 90%H2O/10%D2O, 10 mM bis-
Tris with 10 mMCaCl2 (pH 7.1). Backbone
1H, 13C, and 15N resonance assign-
ments of b2GPI-DV, LA3, LA4, and ApoER2-A1 were carried out by analyzing
HNCA, NHCOCA, HNCACB, and HNCOCACB spectra.
15N-R1 and 15N-R2 relaxation rates were measured in a series of 7–11
experimentswith increased relaxation time delays. To determine the relaxation
rates, the experimentally measured resonance intensities were fitted to a
monoexponential decay model using the xcrvfit program (http://www.
bionmr.ualberta.ca/bds/software/xcrvfit). The overall rotational correlation
time tc was calculated from the R2/R1 ratio using the r2r1_tm program.
Fluorescence Polarization Measurements
Experiments were performed on an EnVision plate reader (Perkin-Elmer) using
480 nm excitation, 535 nm emission filters with 30 nm and 40 nm bandwidths,
respectively, and a FP FITC dual optics module. The LA modules were labeled
with Atto488 (Sigma) according to the manufacturer’s protocol and the labeled
modules were purified by reverse-phase HPLC. Fluorescence polarization
measurements were carried out in 10 mM bis-Tris buffer with 10 mM CaCl2
(pH 7.0). Experiments were performed in triplicates on a 384 well plate using
40 ml of a reaction mixture per well containing either 80 nM LA4, 150 nM
ApoER2-A1, or 130 nM of the LA4 N148/E mutant. GNUPLOT was used to
fit the Kd values to the experimental data via a one-site binding model.
Measurements of the Intrinsic Tryptophan Fluorescence
of b2GPI-DV
Fluorescence measurements were performed on a Spectramax GeminiXS
(Molecular Devices) using a 96 well plate. Each sample contained 100 mM of
b2GPI-DV in 10 mM bis-Tris buffer with 10 mM CaCl2 (pH 7.2) and varied
amounts of LA3. Sampleswere allowed to equilibrate for 25min before spectra
were acquired. The excitation wavelength was set to 280 nm and the emission
scan was read from 330 nm to 400 nm with 1 nm step. To account for the fluo-
rescence of the C-terminal tyrosine of LA3, themeasured fluorescence at each
titration point was corrected for the fluorescence of the blank sample that con-
tained the same amount of LA3 in the absence of b2GPI-DV.Measurements forhts reserved
Structure
Structure of the b2GPI-DV/LA Complexeach sample and blank were done in triplicates using 250 ml sample volume
per well.Molecular Docking with HADDOCK
The coordinates of b2GPI-DV were extracted from the crystal structure of the
full-length protein (PDB code 1c1z), and the structure of LA4 including a
calcium ion was taken from the X-ray structure of the RAP/LA3-4 complex
(PDB code 2fcw). The docking was performed with HADDOCK 2.0 using stan-
dard protocols (Dominguez et al., 2003). The active and passive residues were
selected based on the NMR chemical shift perturbation and the solvent acces-
sibility data. The relative solvent-accessible surface area of residues was
calculatedwith NACCESS v2.1.1 (Hubbard and Thornton, 1993). Only residues
with more than 50% relative solvent accessibility of the main chain or the side
chain were considered. The following solvent-accessible residues perturbed
by complex formation in the NMR titration experiments were designated as
active: K251, K286, K287, K305, K308, E309, W316, D322, K324, and C326
(for b2GPI-DV), and L143, W144, and D149 (for LA4). The passive residues,
defined as solvent-exposed neighbors of the active residues, were P248,
K250, K284, D293, E302, S311, S312, L313, F315, and P325 (for b2GPI-DV),
and Q142, N148, P150, and D151 (for LA4). A 6.0 A˚ cutoff of the pairwise back-
bone rmsd in the interface was used for clustering of 200 refined structures.Cardiolipin Binding Assay
We used 96 well plates precoated with cardiolipin available as part of the
ImmunoWELL cardiolipin IgG test kit (GenBio). We constructed a recombinant
b2GPI-DV with HA epitope tag added to the N terminus of b2GPI-DV
(HA-b2GPI-DV). HA-b2GPI-DV bound to cardiolipin was detected by HRP-
conjugated anti-HA-tag antibodies (Abcam ab1265) using 2-20-azino-di-
[3-ethylbenzthiazoline] sulfonate (ABTS) chromogenic reagent by measuring
OD at 405 nm. All measurements were done in triplicate and corrected to blank
before data fitting. The blank contained all components except for HA-b2GPI-
DV. The assay buffer was 10 mM bis-Tris with 10 mM CaCl2 (pH 7.6). Cardio-
lipin-coated wells were blocked for 1 hr with 0.5% skim milk and 2% bovine
serum albumin in the assay buffer. The binding and inhibition data were fitted
to one-site models using GNUPLOT.
For the binding studies, 50 ml HA-b2GPI-DV was applied to wells and incu-
bated for 30min. After washing, 50 ml anti-HA antibody was added to wells and
incubated for 30 min before detection. In the second set of experiments, 50 ml
HA-b2GPI-DVwas first incubated for 30min with the anti-HA antibodies. Then,
the mixture was applied to cardiolipin, incubated for 30 min, washed, and
bound HA-b2GPI-DV was detected.
For the inhibition studies, 44 nM HA-b2GPI-DV was incubated with LA4 for
30 min. Then, 50 ml of the mixtures was applied to wells and incubated for an
additional 30 min. After washing, 50 ml anti-HA antibody was added to wells
and incubated for 30 min before detection. In the second set of experiments,
50 ml 3.5 nM of HA-b2GPI-DV was first incubated for 20 min with the anti-HA
antibodies. Then, various concentrations of the LA3-4 module-pair were
added to the mixture and incubated for an additional 40 min. The mixture
was applied to cardiolipin, incubated for 30 min, washed, and bound
HA-b2GPI-DV was detected.ACKNOWLEDGMENTS
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